Floatz logo

Psma-Hbed-Cc

Invasive Breast Lobular Carcinoma

Emory UniversityradiopharmaceuticalPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Invasive Breast Lobular Carcinoma cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Vanderbilt-Ingram Cancer Center
Phase 2CCC
Neratinib
Vanderbilt-Ingram Cancer Center
Phase 2CCC
Trastuzumab Emtansine
Vanderbilt-Ingram Cancer Center
Phase 2CCC
Capecitabine
Vanderbilt-Ingram Cancer Center
Phase 2CCC
Vinorelbine
Vanderbilt-Ingram Cancer Center
Phase 2CCC
Fluciclovine
Emory University
Phase 1CC

Same molecule, other indications

Psma-Hbed-Cc is also rated in:

Metastatic Prostate CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
Prostate AdenocarcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →